NLRP3 and epilepsy syndrome: For example, a review of targeted therapies for monogenic epilepsy syndromes suggested that anti-inflammatory drugs, such as steroids or non-steroidal anti-inflammatory drugs, may be beneficial for patients with epilepsy due to mutations in genes involved in the innate immune system, such as NLRP3 or NLRC41 [299].